CLNN Stock Catalyst: FDA Approves Clene Inc.'s Data Submission for ALS Treatment Pathway

May 4, 2026 · 8:03am ET

Regulatory milestone achieved for Clene's proposed drug application.

Max move

+63.0%

High of day $9.78

Sparker timei

8:03am ET

CLNN · May 4, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Clene Inc. (Nasdaq: CLNN) announced that the U.S. Food and Drug Administration (FDA) has approved the company's proposed data as capable for submission and review of a new drug application (NDA) for a treatment pathway targeting Amyotrophic Lateral Sclerosis (ALS).

This regulatory milestone allows Clene to proceed with the formal submission of its NDA, a critical step towards potentially bringing a new therapeutic option to patients suffering from ALS. The company's free float stands at 8,433,000 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time CLNN sparks.

Download Sniper App →

Catch the next CLNN-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →